Reviews Ogen


No reviews yet.

Ogen Drug Description
OGEN
(estropipate) Tablets

WARNINGS
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important.
Adequate diagnostic measures, including endometrial sampling when indicated,
should be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is no evidence that the use
of “natural” estrogens result in a different endometrial risk
profile than “synthetic” estrogens at equivalent estrogen doses.
(See WARNINGS, Malignant neoplasms, Endometrial
cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (see CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women or to women taking estrogen
alone therapy. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
Other doses of conjugated estrogens with
medroxyprogesterone acetate, and other combinations and dosage forms of
estrogens and progestins were not studied in the WHI clinical trials and, in
the absence of comparable data, these risks should be assumed to be similar.
Because of these risks, estrogens with or without progestins should be
prescribed at the lowest effective doses and for the shortest duration
consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of estropipate (Ogen 0.625, Ogen 1.25, Ogen 2.5)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden headache, confusion, problems with...
Read All Potential Side Effects for Ogen »




OGEN (estropipate tablets), (formerly piperazine estrone
sulfate), is a natural estrogenic substance prepared from purified crystalline estrone, solubilized as the sulfate and stabilized with
piperazine. It is appreciably soluble in water and has almost no odor or taste — properties which are ideally suited for oral
administration. The amount of piperazine in OGEN is not sufficient to exert a pharmacological action. Its addition ensures solubility,
stability, and uniform potency of the estrone sulfate. Chemically estropipate, molecular weight: 436.56, is represented by
estra-1,3,5(10)-trien-17-one,3-(sulfooxy)-, compound with piperazine (1:1). The
structural formula may be represented as follows:







OGEN is available as tablets for oral
administration containing either 0.75 mg (OGEN .625), 1.5 mg (OGEN 1.25), or 3
mg (OGEN 2.5) estropipate (Calculated as sodium estrone sulfate 0.625
mg, 1.25 mg, and 2.5 mg, respectively).
Inactive Ingredients
Each tablet contains: Colloidal silicon dioxide, dibasic
potassium phosphate, hydrogenated vegetable oil wax, hydroxypropyl cellulose, lactose, magnesium stearate, microcrystalline
cellulose, sodium starch glycolate and tromethamine.
OGEN .625 also contains: D&C Yellow No. 10 and FD&C
Yellow No. 6.
OGEN 1.25 also contains: FD&C Yellow No. 6.
OGEN 2.5 also contains: FD&C Blue No. 2.Last reviewed on RxList: 4/30/2009




Ogen Drug Description
OGEN
(estropipate) Tablets

WARNINGS
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important.
Adequate diagnostic measures, including endometrial sampling when indicated,
should be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is no evidence that the use
of “natural” estrogens result in a different endometrial risk
profile than “synthetic” estrogens at equivalent estrogen doses.
(See WARNINGS, Malignant neoplasms, Endometrial
cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (see CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women or to women taking estrogen
alone therapy. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
Other doses of conjugated estrogens with
medroxyprogesterone acetate, and other combinations and dosage forms of
estrogens and progestins were not studied in the WHI clinical trials and, in
the absence of comparable data, these risks should be assumed to be similar.
Because of these risks, estrogens with or without progestins should be
prescribed at the lowest effective doses and for the shortest duration
consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of estropipate (Ogen 0.625, Ogen 1.25, Ogen 2.5)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden headache, confusion, problems with...
Read All Potential Side Effects for Ogen »




OGEN (estropipate tablets), (formerly piperazine estrone
sulfate), is a natural estrogenic substance prepared from purified crystalline estrone, solubilized as the sulfate and stabilized with
piperazine. It is appreciably soluble in water and has almost no odor or taste — properties which are ideally suited for oral
administration. The amount of piperazine in OGEN is not sufficient to exert a pharmacological action. Its addition ensures solubility,
stability, and uniform potency of the estrone sulfate. Chemically estropipate, molecular weight: 436.56, is represented by
estra-1,3,5(10)-trien-17-one,3-(sulfooxy)-, compound with piperazine (1:1). The
structural formula may be represented as follows:







OGEN is available as tablets for oral
administration containing either 0.75 mg (OGEN .625), 1.5 mg (OGEN 1.25), or 3
mg (OGEN 2.5) estropipate (Calculated as sodium estrone sulfate 0.625
mg, 1.25 mg, and 2.5 mg, respectively).
Inactive Ingredients
Each tablet contains: Colloidal silicon dioxide, dibasic
potassium phosphate, hydrogenated vegetable oil wax, hydroxypropyl cellulose, lactose, magnesium stearate, microcrystalline
cellulose, sodium starch glycolate and tromethamine.
OGEN .625 also contains: D&C Yellow No. 10 and FD&C
Yellow No. 6.
OGEN 1.25 also contains: FD&C Yellow No. 6.
OGEN 2.5 also contains: FD&C Blue No. 2.Last reviewed on RxList: 4/30/2009




Ogen Drug Description
OGEN
(estropipate) Tablets

WARNINGS
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important.
Adequate diagnostic measures, including endometrial sampling when indicated,
should be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is no evidence that the use
of “natural” estrogens result in a different endometrial risk
profile than “synthetic” estrogens at equivalent estrogen doses.
(See WARNINGS, Malignant neoplasms, Endometrial
cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (see CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women or to women taking estrogen
alone therapy. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
Other doses of conjugated estrogens with
medroxyprogesterone acetate, and other combinations and dosage forms of
estrogens and progestins were not studied in the WHI clinical trials and, in
the absence of comparable data, these risks should be assumed to be similar.
Because of these risks, estrogens with or without progestins should be
prescribed at the lowest effective doses and for the shortest duration
consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of estropipate (Ogen 0.625, Ogen 1.25, Ogen 2.5)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden headache, confusion, problems with...
Read All Potential Side Effects for Ogen »




OGEN (estropipate tablets), (formerly piperazine estrone
sulfate), is a natural estrogenic substance prepared from purified crystalline estrone, solubilized as the sulfate and stabilized with
piperazine. It is appreciably soluble in water and has almost no odor or taste — properties which are ideally suited for oral
administration. The amount of piperazine in OGEN is not sufficient to exert a pharmacological action. Its addition ensures solubility,
stability, and uniform potency of the estrone sulfate. Chemically estropipate, molecular weight: 436.56, is represented by
estra-1,3,5(10)-trien-17-one,3-(sulfooxy)-, compound with piperazine (1:1). The
structural formula may be represented as follows:







OGEN is available as tablets for oral
administration containing either 0.75 mg (OGEN .625), 1.5 mg (OGEN 1.25), or 3
mg (OGEN 2.5) estropipate (Calculated as sodium estrone sulfate 0.625
mg, 1.25 mg, and 2.5 mg, respectively).
Inactive Ingredients
Each tablet contains: Colloidal silicon dioxide, dibasic
potassium phosphate, hydrogenated vegetable oil wax, hydroxypropyl cellulose, lactose, magnesium stearate, microcrystalline
cellulose, sodium starch glycolate and tromethamine.
OGEN .625 also contains: D&C Yellow No. 10 and FD&C
Yellow No. 6.
OGEN 1.25 also contains: FD&C Yellow No. 6.
OGEN 2.5 also contains: FD&C Blue No. 2.Last reviewed on RxList: 4/30/2009




Ogen Drug Description
OGEN
(estropipate) Tablets

WARNINGS
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important.
Adequate diagnostic measures, including endometrial sampling when indicated,
should be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is no evidence that the use
of “natural” estrogens result in a different endometrial risk
profile than “synthetic” estrogens at equivalent estrogen doses.
(See WARNINGS, Malignant neoplasms, Endometrial
cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (see CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women or to women taking estrogen
alone therapy. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
Other doses of conjugated estrogens with
medroxyprogesterone acetate, and other combinations and dosage forms of
estrogens and progestins were not studied in the WHI clinical trials and, in
the absence of comparable data, these risks should be assumed to be similar.
Because of these risks, estrogens with or without progestins should be
prescribed at the lowest effective doses and for the shortest duration
consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of estropipate (Ogen 0.625, Ogen 1.25, Ogen 2.5)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden headache, confusion, problems with...
Read All Potential Side Effects for Ogen »




OGEN (estropipate tablets), (formerly piperazine estrone
sulfate), is a natural estrogenic substance prepared from purified crystalline estrone, solubilized as the sulfate and stabilized with
piperazine. It is appreciably soluble in water and has almost no odor or taste — properties which are ideally suited for oral
administration. The amount of piperazine in OGEN is not sufficient to exert a pharmacological action. Its addition ensures solubility,
stability, and uniform potency of the estrone sulfate. Chemically estropipate, molecular weight: 436.56, is represented by
estra-1,3,5(10)-trien-17-one,3-(sulfooxy)-, compound with piperazine (1:1). The
structural formula may be represented as follows:







OGEN is available as tablets for oral
administration containing either 0.75 mg (OGEN .625), 1.5 mg (OGEN 1.25), or 3
mg (OGEN 2.5) estropipate (Calculated as sodium estrone sulfate 0.625
mg, 1.25 mg, and 2.5 mg, respectively).
Inactive Ingredients
Each tablet contains: Colloidal silicon dioxide, dibasic
potassium phosphate, hydrogenated vegetable oil wax, hydroxypropyl cellulose, lactose, magnesium stearate, microcrystalline
cellulose, sodium starch glycolate and tromethamine.
OGEN .625 also contains: D&C Yellow No. 10 and FD&C
Yellow No. 6.
OGEN 1.25 also contains: FD&C Yellow No. 6.
OGEN 2.5 also contains: FD&C Blue No. 2.Last reviewed on RxList: 4/30/2009




Ogen Drug Description
OGEN
(estropipate) Tablets

WARNINGS
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important.
Adequate diagnostic measures, including endometrial sampling when indicated,
should be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is no evidence that the use
of “natural” estrogens result in a different endometrial risk
profile than “synthetic” estrogens at equivalent estrogen doses.
(See WARNINGS, Malignant neoplasms, Endometrial
cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (see CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women or to women taking estrogen
alone therapy. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
Other doses of conjugated estrogens with
medroxyprogesterone acetate, and other combinations and dosage forms of
estrogens and progestins were not studied in the WHI clinical trials and, in
the absence of comparable data, these risks should be assumed to be similar.
Because of these risks, estrogens with or without progestins should be
prescribed at the lowest effective doses and for the shortest duration
consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION



What are the possible side effects of estropipate (Ogen 0.625, Ogen 1.25, Ogen 2.5)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
sudden numbness or weakness, especially on one side of the body;
sudden headache, confusion, problems with...
Read All Potential Side Effects for Ogen »




OGEN (estropipate tablets), (formerly piperazine estrone
sulfate), is a natural estrogenic substance prepared from purified crystalline estrone, solubilized as the sulfate and stabilized with
piperazine. It is appreciably soluble in water and has almost no odor or taste — properties which are ideally suited for oral
administration. The amount of piperazine in OGEN is not sufficient to exert a pharmacological action. Its addition ensures solubility,
stability, and uniform potency of the estrone sulfate. Chemically estropipate, molecular weight: 436.56, is represented by
estra-1,3,5(10)-trien-17-one,3-(sulfooxy)-, compound with piperazine (1:1). The
structural formula may be represented as follows:







OGEN is available as tablets for oral
administration containing either 0.75 mg (OGEN .625), 1.5 mg (OGEN 1.25), or 3
mg (OGEN 2.5) estropipate (Calculated as sodium estrone sulfate 0.625
mg, 1.25 mg, and 2.5 mg, respectively).
Inactive Ingredients
Each tablet contains: Colloidal silicon dioxide, dibasic
potassium phosphate, hydrogenated vegetable oil wax, hydroxypropyl cellulose, lactose, magnesium stearate, microcrystalline
cellulose, sodium starch glycolate and tromethamine.
OGEN .625 also contains: D&C Yellow No. 10 and FD&C
Yellow No. 6.
OGEN 1.25 also contains: FD&C Yellow No. 6.
OGEN 2.5 also contains: FD&C Blue No. 2.Last reviewed on RxList: 4/30/2009





Other reviews about Ogen on wordpress

Icons and Graphics
  by Sylwia
Go to Austenette Picture Gallery A collection of paintings, illustrations, drawings and sculptures from the long Eighteenth century, including the Regency era. Pictures are arranged into […]


sweetiepie
  by webcamsexen
sweetiepie (22 jaar)Woonplaats: AmsterdamLand: NederlandGeaardheid: bisexueelKleur haar: blondKleur ogen: groenLichaamsbouw: slankMy dream is to be with you right now.. My fantasy is to have a great time with […]


2_for_u
  by webcamsexen
2_for_u (25 jaar)Woonplaats: BogotaLand: ColombiaGeaardheid: bisexueelKleur haar: zwartKleur ogen: bruinLichaamsbouw: slankBaby we are so hot and wet now and ready for sexy games with u. Very big tits, […]


Adsorption of Fibrinogen to Droplets of Liquid Hydrophobic Phases: Functionality of the Bound Protein and Biological Implications
  by esal
Adsorption of Fibrinogen to Droplets of Liquid Hydrophobic Phases: Functionality of the Bound Protein and Biological Implications Gregory S. Retzinger, Ashley P. DeAnglis and Samantha J. Patuto Arterioscler. Thromb. […]


Fibrinogen-Coated Droplets of Olive Oil for Delivery of Docetaxel to a Fibrin(ogen)-Rich Ascites Form of a Murine Mammary Tumor
  by esal
Fibrinogen-Coated Droplets of Olive Oil for Delivery of Docetaxel to a Fibrin(ogen)-Rich Ascites Form of a Murine Mammary Tumor Charity M¹. Einhaus¹, Andre O. Perrotta¹, Andrew C. Retzinger¹, Michael […]


08/01 - ogen
  by stijn
08/01 - ogen, originally uploaded by stijnh.


mooikonijn
  by webcamsexblog
mooikonijn (23 jaar)Woonplaats: BacauLand: RoemeniëGeaardheid: bisexueelKleur haar: zwartKleur ogen: bruinLichaamsbouw: slankI am a sensitive girl with a great body and sexy smile. I am sweet, naughty, gorgeous and […]


cristine
  by cammeiden
cristine (26 jaar)Woonplaats: ClujLand: RoemeniëGeaardheid: bisexueelKleur haar: donkerblondKleur ogen: bruinLichaamsbouw: slankWOW!!! Best BodY GreaT SmilE SexY Outfits and matching Attitude Share your Secret Desires with me, Im here […]


darlyn
  by cammeiden
darlyn (20 jaar)Woonplaats: BogotaLand: ColombiaGeaardheid: bisexueelKleur haar: bruinKleur ogen: bruinLichaamsbouw: slankAre you just like me and do you like to have sex every day? You really have to […]


shira
  by webcamsexblog
shira (25 jaar)Woonplaats: BogotaLand: ColombiaGeaardheid: bisexueelKleur haar: zwartKleur ogen: bruinLichaamsbouw: slankAll my nights I take a warm shower and cross every corner of my body with my fingers […]



Other reviews about Ogen on web:

Learn about the prescription medication Ogen (Estropipate), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Ogen (Estropipate) Drug Information: Uses, Side Effects, Drug ...


Accurate, FDA approved Ogen information for healthcare professionals and patients - brought to you by Drugs.com. Ogen Official FDA information, side effects and uses.


All about Ogen. View complete and up to date Ogen information - part of the Drugs.com trusted medication database. Ogen Facts and Comparisons at Drugs.com


PATIENT INFORMATION (Updated July 2006) OGEN ® estropipate tablets, USP Read this PATIENT INFORMATION before you start taking OGEN and read what you get each time you refill OGEN. OGEN®


Estropipate is a form of estrogen sold under the brand names Ogen and Ortho-Est. It is a salt of estrone sulfate and piperazine. Uses. Estropipate is used to: Estropipate - Wikipedia, the free encyclopedia


Ogen is a prescription medication most commonly used for treating menopause symptoms. This eMedTV resource covers other uses of the drug and offers a more in-depth look at its ... Ogen


Information on OGEN tablets from Pfizer. ... OGEN ® Tablets (estropipate tablets, USP) This product information is intended only for residents of the United States. OGEN Tablets | Pfizer: the world's largest research-based ...


OGEN CREATIVE SERVICES, Custom advertising solutions at competitive prices. Our imaginative marketing/advertising results help achieve our clients business goals and profitability Ogen Creative Services


Recent Published Jury Verdicts & Settlements . $2.45 Million Pre-Trial Settlement read more . $1.375 Million Jury verdict ... read more . $1.3 Million Jury Verdict for 35 year old ... Ogen & Sedaghati, P.C. Personal Injury Lawyers


Find lowest price for a Ogen prescription. Save up to 70% on drug prices at verified online pharmacies. Buy Ogen Online | Compare Ogen Prices & Save - Pharmahelper.com





Featured Reviews

Reviews Vitamin A, D, C, and Fluoride

Triple Vita Drops with Fluoride Drug Description Triple Vita Drops with Fluoride 0.25 mg DRUG DESCRIPTION Each 1.0 mL supplies: Percentage of U. S. Recommended Daily Allowance Infants Children Under Age 4 Years ...
Read More  |  Review This
Reviews Human)

Mononine Drug Description Mononine® Coagulation Factor IX (Human) Monoclonal Antibody Purified DRUG DESCRIPTION What are the possible side effects of coagulation factor IX (Alphanine SD, Benefix, Mononine)? Get emergency...
Read More  |  Review This
Reviews Altabax

Altabax Drug Description ALTABAX (retapamulin) DRUG DESCRIPTION What are the possible side effects of retapamulin topical (Altabax)? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty...
Read More  |  Review This
Reviews Vusion

Vusion Drug Description VUSION® (miconazole nitrate, zinc oxide, and white petrolatum) Ointment, for Topical Use Only DRUG DESCRIPTION VUSION contains the synthetic antifungal agent, miconazole nitrate (0.25%) USP, zinc oxide (15%)...
Read More  |  Review This
Reviews Acticin

Acticin Drug Description DRUG DESCRIPTION Acticin (permethrin) Cream 5% Acticin (permethrin) Cream 5% is a topical scabicidal agent for the treatment of infestation with Sarcoptes scabiei (scabies). It is available in an off- white,...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....